We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.5%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.7B
AUM Growth
-$152M
Cap. Flow
+$293M
Cap. Flow %
3.03%
Top 10 Hldgs %
29.73%
Holding
234
New
14
Increased
60
Reduced
64
Closed
43

Top Buys

Rank Stock Value
1
CDNA icon
CareDx
CDNA
+$74.9M
2
ABT icon
Abbott
ABT
+$45.9M
3
MOH icon
Molina Healthcare
MOH
+$43.5M
4
DHR icon
Danaher
DHR
+$42M
5
MDT icon
Medtronic
MDT
+$38M

Top Sells

Rank Stock Value
1
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$63.1M
2
BAX icon
Baxter International
BAX
+$38.1M
3
CNC icon
Centene
CNC
+$36.2M
4
HOLX
Hologic
HOLX
+$21.4M
5
DXCM icon
DexCom
DXCM
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.85%
2 Technology 0.8%
3 Industrials 0.75%
4 Communication Services 0.02%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
51
Bristol-Myers Squibb
BMY
$124B
$66M 0.68%
1,059,347
-243,587
-19% -$14.3M
TMO icon
52
Thermo Fisher Scientific
TMO
$198B
$65.6M 0.68%
98,328
+11,449
+13% +$7.15M
OMCL icon
53
Omnicell
OMCL
$2.09B
$65.4M 0.67%
362,332
-31,251
-8% -$5.42M
NKTR icon
54
Nektar Therapeutics
NKTR
$2.31B
$60.1M 0.62%
296,780
-9,530
-3% -$2.07M
REGN icon
55
Regeneron Pharmaceuticals
REGN
$70.9B
$58.8M 0.61%
93,060
-13,350
-13% -$8.21M
SRRK icon
56
Scholar Rock
SRRK
$6.33B
$57M 0.59%
2,294,425
– –
CI icon
57
Cigna
CI
$74.5B
$56.3M 0.58%
245,174
+27,362
+13% +$5.81M
PEN icon
58
Penumbra
PEN
$12.5B
$55.7M 0.57%
193,734
-11,958
-6% -$3.16M
ADPT icon
59
Adaptive Biotechnologies
ADPT
$3.67B
$55.2M 0.57%
1,968,431
+632,408
+47% +$19.4M
GMED icon
60
Globus Medical
GMED
$10.5B
$54.7M 0.56%
757,464
+28,044
+4% +$2.04M
CNC icon
61
Centene
CNC
$32.8B
$54.4M 0.56%
660,010
-494,535
-43% -$36.2M
ABMD
62
DELISTED
Abiomed Inc
ABMD
$53.9M 0.56%
150,178
-1,000
-0.7% -$338K
RDUS
63
DELISTED
Radius Health, Inc.
RDUS
$53.8M 0.55%
7,768,714
– –
EXEL icon
64
Exelixis
EXEL
$14.1B
$52.3M 0.54%
2,859,000
– –
EXAS
65
DELISTED
Exact Sciences
EXAS
$50M 0.52%
642,582
+213,309
+50% +$18.8M
BEAM icon
66
Beam Therapeutics
BEAM
$2.83B
$48.8M 0.5%
612,821
– –
IQV icon
67
IQVIA
IQV
$34.4B
$46.1M 0.48%
163,520
-27,100
-14% -$7.03M
HOLX
68
DELISTED
Hologic
HOLX
$44.4M 0.46%
579,424
-291,238
-33% -$21.4M
HALO icon
69
Halozyme
HALO
$9.23B
$42.9M 0.44%
1,067,500
+146,000
+16% +$5.45M
MTEM
70
DELISTED
Molecular Templates, Inc.
MTEM
$42.6M 0.44%
725,200
– –
VEEV icon
71
Veeva Systems
VEEV
$31.7B
$42.1M 0.43%
164,955
-9,596
-5% -$2.79M
ABBV icon
72
AbbVie
ABBV
$450B
$41.6M 0.43%
306,900
+24,000
+8% +$2.84M
SILK
73
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$40.6M 0.42%
952,433
+170,773
+22% +$8.54M
HZNP
74
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$39.7M 0.41%
368,600
-47,600
-11% -$5.19M
BAX icon
75
Baxter International
BAX
$11.7B
$38.6M 0.4%
449,849
-473,374
-51% -$38.1M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2021 Portfolio in Review

As of Q4 2021, Bellevue Group held 234 positions worth $9.7B, down 1.5% from $9.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group deployed $293M of net new capital in Q4 2021, opening 14 new positions and adding to 60 existing holdings. Its largest new stake was AstraZeneca: 29,500 shares worth $3.44M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Baxter International, an estimated $38.1M trimmed.

  • Bellevue Group's largest Q4 2021 buy was AstraZeneca: 29,500 shares worth $3.44M.
  • Bellevue Group added most to CareDx in Q4 2021, an estimated $74.9M increase.
  • Bellevue Group's biggest Q4 2021 reduction was Baxter International, cutting an estimated $38.1M.
  • Bellevue Group fully exited HILL-ROM HOLDINGS, INC. in Q4 2021, selling an estimated $63.1M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.7B portfolio in Q4 2021.
  • Bellevue Group opened 14 new positions and closed 43 in Q4 2021.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $9.7B.

Based on Bellevue Group's 13F filing for Q4 2021, filed 10 Feb 2022.